首站-论文投稿智能助手
典型文献
The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages
文献摘要:
The recently discovered SARS-CoV-2 variant Omicron(B.1.1.529)has rapidly become a global public health issue.The substantial mutations in the spike protein in this new variant have raised concerns about its ability to escape from pre-existing immunity established by natural infection or vaccination.In this review,we give a summary of current knowledge concerning the antibody evasion properties of Omicron and its subvariants(BA.2,BA.2.12.1,BA.4/5,and BA.2.75)from therapeutic monoclonal antibodies and the sera of SARS-CoV-2 vaccine recipients or convalescent patients.We also summarize whether vaccine-induced cellular immunity(memory B cell and T cell response)can recognize Omicron specifically.In brief,the Omicron variants demonstrated remarkable antibody evasion,with even more striking antibody escape seen in the Omicron BA.4 and BA.5 sub-lineages.Luckily,the third booster vaccine dose significantly increased the neutralizing antibodies titers,and the vaccine-induced cellular response remains conserved and provides second-line defense against the Omicron.
文献关键词:
作者姓名:
Tiandan Xiang;Junzhong Wang;Xin Zheng
作者机构:
Department of Infectious Diseases,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Joint International Laboratory of Infection and Immunity,Huazhong University of Science and Technology,Wuhan 430022,China
文献出处:
引用格式:
[1]Tiandan Xiang;Junzhong Wang;Xin Zheng-.The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages)[J].中国病毒学,2022(06):786-795
A类:
subvariants
B类:
humoral,cellular,immune,evasion,SARS,CoV,Omicron,lineages,recently,discovered,has,rapidly,become,global,public,health,issue,substantial,mutations,spike,protein,this,new,have,raised,concerns,about,its,ability,escape,from,pre,existing,immunity,established,by,natural,infection,vaccination,In,review,we,give,summary,current,knowledge,concerning,antibody,properties,BA,therapeutic,monoclonal,antibodies,sera,vaccine,recipients,convalescent,patients,We,also,summarize,whether,induced,memory,response,recognize,specifically,brief,demonstrated,remarkable,even,more,striking,seen,Luckily,third,booster,dose,significantly,increased,neutralizing,titers,remains,conserved,provides,second,defense,against
AB值:
0.607867
相似文献
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice,rabbits and NHPs
Zezhong Liu;Jie Zhou;Wei Xu;Wei Deng;Yanqun Wang;Meiyu Wang;Qian Wang;Ming Hsieh;Jingming Dong;Xinling Wang;Weijin Huangei;Lixiao Xing;Miaoling He;Chunlin Tao;Youhua Xie;Yilong Zhang;Youchun Wang;Jincun Zhao;Zhenghong Yuan;Chuan Qin;Shibo Jiang;Lu Lu-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Blosecurity;Biosafety Level 3 Laboratory,Shanghai Medical College,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Fudan University,Shanghai,China;Key Laboratory of Human Disease Comparative Medicine,National Health Commission of the People's Republic of China;Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Guangzhou Laboratory,Bio-Island,Guangzhou,China;Graduate School of Peking Union Medical College,No.9 Dongdan Santiao,Dongcheng District,Beijing,China;Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC),No.31 Huatuo Street,Daxing District,Beijing,China;Fulgent Pharma LLC.,4978 Santa Anita Avenue,Temple City,CA,USA
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Shuai Xia;Jasper Fuk-Woo Chan;Lijue Wang;Fanke Jiao;Kenn Ka-Heng Chik;Hin Chu;Qiaoshuai Lan;Wei Xu;Qian Wang;Chao Wang;Kwok-Yung Yuenuai;Lu Lu;Shibo Jiang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China;Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China;State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacoloay and Toxicoloay,Beijing,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins
Youwei Xu;Canrong Wu;Xiaodan Cao;Chunyin Gu;Heng Liu;Mengting Jiang;Xiaoxi Wang;Qingning Yuan;Kai Wu;Jia Liu;Deyi Wang;Xianqing He;Xueping Wang;Su-Jun Deng;H.Eric Xu;Wanchao Yin-The CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;Shanghai Jemincare Pharmaceuticals Co.,Ltd.,Shanghai,China;School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing,Jiangsu,China;The Shanghai Advanced Electron Microscope Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;University of Chinese Academy of Sciences,Beijing,China;School of Life Science and Technology,ShanghaiTech University,Shanghai,China;Zhongshan Institute for Drug Discovery,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Guangdong,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang;Ying Lu;Yan-Bo Zhao;Fan Shen;Chang-Fa Fan;Qian Wang;Wen-Qiang He;Xiao-Yan He;Ze-Kai Li;Tao-Tao Chen;Cui-Xian Yang;You-Zhi Li;Si-Xuan Xiao;Zu-Jiang Zhao;Xu-Sheng Huang;Rong-Hua Luo;Liu-Meng Yang;Mi Zhang;Xing-Qi Dong;Ming-Hua Li;Xiao-Li Feng;Qing-Cui Zhou;Wang Qu;Shibo Jiang;Songying Ouyang;Yong-Tang Zheng-Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province,KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China;University of the Chinese Academy of Sciences,Beijing,China;The Key Laboratory of Innate Immune Biology of Fujian Province,Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation,Biomedical Research Center of South China,Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education,College of Life Sciences,Fujian Normal University,Fuzhou,Fujian,China;Division of Animal Model Research,Institute for Laboratory Animal Resources,National Institutes for Food and Drug Control,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,School of Basic Medical Sciences,Fudan University,Shanghai,China;Yunnan Provincial Infectious Disease Hospital,Kunming,Yunnan,China;Kunming National High-level Biosafety Research Center for Non-human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。